FY4/19 3Q IR PRESENTATION

AIN HOLDINGS INC. March 2019

Results Overview



Consolidated P/L

Net sales increased 1.2% year on year to $\pm 202,522$ million, operating income declined 16.8% to $\pm 11,909$ million, ordinary income dropped 15.8% to $\pm 12,425$ million, and profit attributable to owners of parent decreased 14.5% to $\pm 6,781$ million.

(¥ million)	FY4/18 3Q results	FY4/19 3Q plan	FY4/19 3Q results	YoY change	YoY change(%)	Vs plan (%)
Net sales	200,043	202,890	202,522	+2,479	+1.2	(0.2)
Gross profit % of net sales	35,193 17.6	35,110 17.3	33,753 16.7	(1,440)	(4.1)	(3.9)
SG&A expenses % of net sales	20,883 10.4	22,850 11.3	21,844 10.8	+961	+4.6	(4.4)
Operating income % of net sales	14,310 7.2	12,260 6.0	11,909 5.9	(2,401)	(16.8)	(2.9)
Ordinary income % of net sales	14,760 7.4	12,630 6.2	12,425 6.1	(2,335)	(15.8)	(1.6)
Profit attributable to owners of parent % of net sales	7,931 4.0	6,650 3.3	6,781 3.3	(1,150)	(14.5)	+2.0
Earnings per share(¥)	235.74	187.71	191.41	(44.33)	(18.8)	+2.0

Figures in the table are rounded down



Dispensing Pharmacy Business (Consolidated)

Net sales increased 0.7% year on year and 0.7% against the plan due to the drug price that exceed the expectation and stores opened in the previous fiscal year made a significant contribution to sales. Segment income decreased 5.3% against the plan due to the shortness for making up the upfront investment for new store openings.

(¥ million)	FY4/18 3Q results	FY4/19 3Q plan	FY4/19 3Q results	YoY change	YoY change(%)	Vs plan (%)
Net sales	178,136	178,220	179,397	+1,261	+0.7	+0.7
Gross profit % of net sales	26,273 14.7	25,090 14.1	24,216 13.5	(2,057)	(7.8)	(3.5)
SG&A expenses % of net sales	10,747 6.0	11,360 6.4	11,112 6.2	+365	+3.4	(2.2)
Operating income % of net sales	15,525 8.7	13,730 7.7	13,104 7.3	(2,421)	(15.6)	(4.6)
Segment income % of net sales	16,013 9.0	14,240 <mark>8.0</mark>	13,488 7.5	(2,525)	(15.8)	(5.3)
Number of pharmacies	1,041	1,092	1,083	+42	+4.0	(0.8)

Figures in the table are rounded down

> Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income

- Prescription volume: +4.2% YoY
- Average prescription price: (3.1)%YoY



Cosmetic and Drug Store Business (Consolidated)

Although the net sales of existing stores has showing steadily growth, net sales increased 6.5 % year on year and decreased 6.0% against the plan due to the series of natural disaster. Segment income decreased 9.1% against the plan due to net sales unachieved.

(¥ million)	FY4/18 3Q results	FY4/19 3Q plan	FY4/19 3Q results	YoY change	YoY change(%)	Vs plan (%)
Net sales	17,779	20,140	18,927	+1,148	+6.5	(6.0)
Gross profit % of net sales	6,647 37.4	7,510 37.3	7,085 37.4	+438	+6.6	(5.7)
SG&A expenses % of net sales	6,257 35.2	6,710 33.3	6,403 33.8	+146	+2.3	(4.6)
Operating income % of net sales	390 2.2	800 4.0	682 3.6	+292	+74.9	(14.7)
Segment income % of net sales	425 2.4	815 4.0	741 3.9	+316	+74.4	(9.1)
Number of stores	48	52	52	+4	+8.3	0.0

Figures in the table are rounded down

Segment income is adjusted to ordinary income shown on the quarterly consolidated statements of income

Number of customers: +3.0% YoY

Average spending per customer: +3.4% YoY

Consolidated B/S

Net cash was ¥38,696 million and shareholders' equity ratio became 55.5%. We are maintaining a sound financial structure.

	(¥ million)	_				(¥ million)
End-F	Y4/18			End-FY	4/19 3Q	
Assets	Liabilities		Asset	.s	Liabilit	ies
Current assets Cash on hand and in banks 63,779	Current liabilities Short-term debt Lease obligations 443		Current assets Cash on hand and in banks	88,391 53,494	Current liabilities Short-term debt Lease obligations	69,235 6,935 346
Fixed assets Investments in securities 88,718 2,375	Long-term liabilities16,696Long-term debt Lease obligations11,511632		Fixed assets Investments in securities	94,567 2,267	Long-term liabilities Long-term debt Lease obligations	12,118 7,020 495
Deferred 103 assets	Total net assets 96,733		Deferred assets	70	Total net assets	101,674
Total assets 183,380	Total liabilities and net assets 183,380		Total assets	183,029	Total liabilities and net assets	183,029
Net cash	44,474		Net cash			38,696
Shareholders' equity ratio(%)	52.7		Shareholders' ratio(%)	equity		55.5

Figures in the table are rounded down

Net cash = Cash on hand and in banks – Interest-bearing debt (Long- and short- term debt + Lease obligations)



Assets

The balance of total assets decreased ¥351 million from the end of the previous fiscal year due to the decrease of cash on hand and in banks while inventories has increased.

(¥ million)	End-FY4/18 3Q	End-FY4/18	End-FY4/19 3Q	Change	
Cash on hand and in banks	60,572	63,779	53,494	(10,285)	Repayment
Notes and accounts receivable	10,269	10,466	11,172	+706	of debts
Inventories	12,482	9,580	12,725	+3,145	New store
Total current assets	92,976	94,557	88,391	(6,166)	openings
Buildings and structures, net	15,228	14,934	15,978	+1,044	
Land	10,150	10,041	10,368	+327	
Lease assets	941	824	695	(129)	
Total property,plant and equipment	28,253	27,853	29,660	+1,807	
Goodwill	38,476	38,011	40,138	+2,127	M&A
Lease assets	12	11	10	(1)	
Total intangible fixed assets	40,489	40,132	42,352	+2,220	
Investments in securities	2,389	2,375	2,267	(108)	
Deferred tax assets	3,369	3,772	3,989	+217	
Deposits and guarantees	10,740	11,339	12,832	+1,493	
Total investments and other assets	20,344	20,732	22,553	+1,821	
Total fixed assets	89,087	88,718	94,567	+5,849	
Total deferred assets	114	103	70	(33)	
Total assets	182,178	183,380	183,029	(351)	

Figures in the table are rounded down Change:End-FY4/19 3Q compared with End-FY4/18

Capital expenditures (Property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled ¥5,766million



Liabilities and Net Assets

The balance of liabilities decreased ¥5,292 million from the end of the previous fiscal year due to the repayment of debts etc.

(¥ million)	End-FY4/18 3Q	End-FY4/18	End-FY4/19 3Q	Change	
Accounts payable	41,351	38,728	43,016	+4,288	
Short-term debt	8,207	6,717	6,935	+218	
Lease obligations	475	443	346	(97)	
Total current liabilities	69,831	69,950	69,235	(715)	
Long-term debt	13,012	11,511	7,020	(4,491)	> <u> </u>
Lease obligations	734	632	495	(137)	Repayment of debts
Total long-term liabilities	18,088	16,696	12,118	(4,578)	
Total liabilities	87,920	86,646	81,354	(5,292)	
Common stock	21,894	21,894	21,894	-	
Capital surplus	20,500	20,500	20,500	-	
Retained earnings	51,632	54,268	59,278	+5,010	
Total shareholders' equity	94,026	96,662	101,672	+5,010	
Total net assets	94,257	96,733	101,674	+4,941	
Total liabilities and net assets	182,178	183,380	183,029	(351)	

Figures in the table are rounded down

Change : End-FY4/19 3Q compared with End-FY4/18



FY4/19 Plan (Consolidated)

The group forecasts net sales for the fiscal year ending April 30, 2019 of 272,870 million, increase 1.7% year on year by openings new stores (100 pharmacies and 7 Cosmetic and drug stores), ordinary income decrease 10.6% due to the dispensing fee revisions.

(¥ million)	FY4/17 results	FY4/18 results	FY4/19 plan	YoY change	YoY change (%)
Net sales	248,110	268,385	272,870	+4,485	
Gross profit	42,092	47,993	48,040	+47	+0.1
% of net sales	17.0	17.9	17.6		
SG&A expenses	27,529	28,370	30,540	+2,170	+7.6
% of net sales	11.1	10.6	11.2		
Operating income	14,563	19,622	17,500	(2,122)	(10.8)
% of net sales	5.9	7.3	6.4		
Ordinary income	15,080	20,129	18,000	(2,129)	(10.6)
% of net sales	6.1	7.5	6.6		
Profit attributable to	7,949	10,567	9,260	(1,307)	(12.4)
owners of parent % of net sales	3.2	3.9	, 3.4		
Earnings per share(¥)	250.71	310.08	261.38	(48.70)	(15.7)
Annual dividend (¥)	50.00	50.00	55.00	+5.00	+10.0

Figures in the table are rounded down


> YoY change :FY4/19 plan compared with FY4/18 results

3Q Review

Review 1 (YoY)

					Net sales	
(¥ million)	FY4/18 3Q results	FY4/19 3Q results	YoY change	YoY change (%)	+¥6.8 billion New stores Impact of	
Net sales	200,043	202,522	2,479	+1.2	+¥4.9 billion	¥(2.5) billion Close of ¥2.5
Gross profit % of net sales	35,193 17.6	33,753 16.7	(1,440)	(4.1)	Full contribution of store that opened in previous fiscal year FY4/18 3Q results	unprofitable stores billion 1.2% FY4/19 3Q results
SG&A expenses % of net sales	20,883 10.4	21,844 10.8	+961	+4.6	 Ordinary income 	results
Operating income % of net sales Ordinary	14,310 7.2	11,909 5.9	(2,401)	In	+¥0.3 billion nprovement of ssmetic and rug store +¥0.2 billion Improvement of AYURA ¥(2.5)	FY4/19 3Q results
income % of net sales	14,760 7.4	12,425 6.1	(2,335)		FY4/18 3Q results FY4/18 inpact of revision	of
Figures in th © 2019 AIN HOL	e table are rou DINGS INC. All Rights					¥(2.3) billion ¥(0.3) billion Increase of head office expense 10


Review² (Vs plan)




Response to revision of 2018


Object: 988 stores, which including existing stores and stores opening in FY4/18

Basic dispensing fee



Community support system premiums





© 2019 AIN HOLDINGS INC. All Rights Reserved.

18.5

17.5

15.3


1/19

Top-line

The group has achieved the initial plan of M&A in end of the third quarter. Total number of store opening in end-FY4/19 will greatly exceeds the initial plan since the group is intend to acquire TSUCHIYA YAKUHIN INC. on March 28, 2019, which operates 36 dispensing pharmacies in Nagano Prefecture.

Total number of stores

1,135 (Dispensing pharmacy:1,083 Cosmetic and drug store:52)



FY4/17-FY4/18 The number of closure store in dispensing pharmacy : closed 63, sold 34

EV/EBITDA ratio=EV(Purchase price)/EBITDA(Operating income + Depreciation and amortization)
 © 2019 AIN HOLDINGS INC. All Rights Reserved.

FY4/19 Plan (Dispensing Pharmacy Business)

(¥ million)	FY4/18 results	FY4/19 plan	YoY change	YoY change (%)	+¥12.1 billion New 100 store Figure 100
Net sales	238,645	239,800	+1,155	+0.5	¥(4.0) billion Store Closing in current
Gross profit % of net sales	36,030 15.1	34,500 14.4	(1,530)	(4.2)	+¥4.9 billion and previous year Full contribution of stores +¥1.1 billion +0.5%
SG&A expenses % of net sales	14,034 5.9		+1,166	+8.3	FY4/18FY4/19resultsplanSegment income
Operating income % of net sales	21,995 <mark>9.2</mark>	19,300 <mark>8.0</mark>	(2,695)	(12.3)	¥(2.3) billion Impact of revision ¥(1.6) billion Store closing in current
Segment income % of net sales	22,668 9.5	20,000 8.3	(2,668)	(11.8)	+¥6.3 billionand previous yearContribution of stores that opened in current and previous year¥(4.4) billion Increase of labor costs and operationFY4/19
Figures in the ta	ble are round	ed down			FY4/18cost by recruitment and new store opening¥(2.6) billion (11.8)%

Net sales

billion Head office expense, etc.

Expansion of AINZ & TULPE

Location

Open

Sales floor

ABENO HOOP

Apr 10, 2019

(plan)


301m²



	UMEDA HEPFIVE
Location	Kita-ku, Osaka
Open	Apr 19, 2019 (plan)
Sales floor	566m ²



Expansion of AINZ & TULPE



© 2019 AIN HOLDINGS INC. All Rights Reserved.

FY4/19 Plan (Cosmetic and Drug Store Business)

(¥ million)	FY4/18 results	FY4/19 plan	YoY change	YoY change (%)	 Net sales +¥1.2 billion New 7 stores ¥(0.7) Closed in previous year stores +¥0.7 billion
Net sales	24,117	27,000	+2,883	+12.0	Full contribution of opening in previous year+¥2.8 Billion +12.0%+¥1.6 billion Growth of ovicting
Gross profit % of net sales	8,925 37.0	10,060 37.3	+1,135	+12.7	Growth of existing stores FY4/18 FY4/19 results plan
SG&A expenses % of net sales	8,317 34.5	9,060 33.6	+743	+8.9	 Segment income
Operating income % of net sales	608 2.5	1,000 3.7	+392	+64.5	+¥0.07 billion Improvement of gross margin ¥(0.78) billion Cost of new opening store Cost of product development
Segment income % of net sales	657 2.7	1,020 3.8	+363	+55.3	+¥1.07 billion +¥0.36 Growth of net sales billion +55.3%
Figures in the table	e are rounded	down			FY4/18 FY4/19 results plan



FY4/19 Plan (Consolidated)

The group forecasts net sales for the fiscal year ending April 30, 2019 of 272,870 million, increase 1.7% year on year by openings new stores (100 pharmacies and 7 Cosmetic and drug stores), ordinary income decrease 10.6% due to the dispensing fee revisions.

(¥ million)	FY4/17 results	FY4/18 results	FY4/19 plan	YoY change	YoY change (%)
Net sales	248,110	268,385	272,870	+4,485	+1.7
Gross profit	42,092	47,993	48,040	+47	+0.1
% of net sales	17.0	17.9	17.6		
SG&A expenses	27,529	28,370	30,540	+2,170	+7.6
% of net sales	11.1	10.6	11.2		
Operating income	14,563	19,622	17,500	(2,122)	(10.8)
% of net sales	5.9	7.3	6.4		
Ordinary income	15,080	20,129	18,000	(2,129)	(10.6)
% of net sales	6.1	7.5	6.6		
Profit attributable to	7,949	10,567	9,260	(1,307)	(12.4)
owners of parent % of net sales	3.2	3.9	3.4		
Earnings per share(¥)	250.71	310.08	261.38	(48.70)	(15.7)
Annual dividend (¥)	50.00	50.00	55.00	+5.00	+10.0

Figures in the table are rounded down

> YoY change :FY4/19 plan compared with FY4/18 results

Supplementary Information

Dispensing Fee Revisions of 2018

- Basic dispensing fee (New classification requirements)
- 1 41 pts
- 2 25 pts Over 4,000 times & 70% or Over 2,000 times & Over **85%** or Over 4,000 times from specific hospital
- 3- I 20 pts Same group over 40,000 times / month & Over 85% or lease contract with medical institution

3-I 15 pts Same group over 400,000 times / month & Over 85% or lease contract with medical institution


- S 10 pts Same premises (lease contract) & Over 95%
- Community support system premiums (New) 35 pts


Companies with annual net sales of approximately 43 billion yen or above

Basic dispensing fee 1, Inventory 1,200 items & Home healthcare services & Primary care pharmacists & Supervising pharmacist having experience 5 years, staying 1 year, 32h/week **Other than basic dispensing fee 1, have to fulfill all the following achievements**


 GE Premiums (Requirements changed) 75-80% 18pts, 80-85% 22pts, Over 85% 26pts 	Per pharmacists per year ①Night · Holiday addition 400 times ②Narcotic drug management guidance addition 10
 Drug use history management and guidance fee (3 classifications) 41pts BDF 41pts & handing over medication notebook & visiting within 6 months 53pts Except the above 13pts handing over medication notebook ratio under 50% 	times ③Duplicate medication · Interaction prevention addition 40 times ④Primary care pharmacists instruction fee 40 times ⑤Outpatient medication support fee 12 times ⑥Medication adjustment support addition 1 times ⑦Home care services 12 times ⑧Medication information providing fee 60 times
Primary care pharmacists instruction fee (Requirements changed)	
73pts Patient's consent & 3 years experience • Staying 1 year • 32h/week, etc.	

Company Profile





Comparison to Other Companies



^{© 2019} AIN HOLDINGS INC. All Rights Reserved.

Inquiries related to this presentation should be addressed to

AIN HOLDINGS INC. Corporate Planning Division TEL(81)11-814-0010 FAX(81)11-814-5550 http://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.

